Health care stocks were flat to higher premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5%.
CytomX Therapeutics (CTMX) shares were up more than 50% after the company said a phase 1 clinical trial evaluating varsetatug masetecan in patients with advanced colorectal cancer yielded confirmed response rates of up to 32%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments